Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Launay-Vacher

Showing results (1-10 of 126) with videos related to

Pageof 13
Sort By:
Seminars in Nephrology|December 15, 2010
Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study groupVincent Launay-Vacher
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2016
Renal Dysfunction Has Statistically and Clinically Significant Deleterious Effects on Anticancer Drug SafetyVincent Launay-Vacher
Cancer Chemotherapy and Pharmacology|September 24, 2013
An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needsVincent Launay-Vacher
Bulletin Du Cancer|April 25, 2012
[Kidney and cancer: cross-over management]Juliette Thariat, Vincent Launay-Vacher
Seminars in Dialysis|April 14, 2015
Anticancer Drugs in End-Stage Kidney Disease PatientsNicolas Janus, Vincent Launay-Vacher
Expert Opinion on Drug Metabolism & Toxicology|May 25, 2017
Pharmacokinetic/pharmacodynamic considerations for cancer patients undergoing hemodialysisNicolas Janus, Vincent Launay-Vacher
Anti-Cancer Drugs|April 4, 2009
Hypertension and proteinuria: a class-effect of antiangiogenic therapiesVincent Launay-Vacher, Gilbert Deray
Cancer Treatment Reviews|May 25, 2011
Importance of monitoring renal function in patients with cancerMatti Aapro, Vincent Launay-Vacher
Bulletin Du Cancer|December 3, 2011
[Treatments of metastases in cancer]Joseph Gligorov, Vincent Launay-Vacher, Matti Aapro
The New England Journal of Medicine|September 9, 2005
Viral load and HIV-associated nephropathyHassane Izzedine, Marc Wirden, Vincent Launay-Vacher
Pageof 13

Showing results (1-10 of 126) with videos related to

Sort By:
Pageof 13
Seminars in Nephrology|December 15, 2010
Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study groupVincent Launay-Vacher
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2016
Renal Dysfunction Has Statistically and Clinically Significant Deleterious Effects on Anticancer Drug SafetyVincent Launay-Vacher
Cancer Chemotherapy and Pharmacology|September 24, 2013
An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needsVincent Launay-Vacher
Bulletin Du Cancer|April 25, 2012
[Kidney and cancer: cross-over management]Juliette Thariat, Vincent Launay-Vacher
Seminars in Dialysis|April 14, 2015
Anticancer Drugs in End-Stage Kidney Disease PatientsNicolas Janus, Vincent Launay-Vacher
Expert Opinion on Drug Metabolism & Toxicology|May 25, 2017
Pharmacokinetic/pharmacodynamic considerations for cancer patients undergoing hemodialysisNicolas Janus, Vincent Launay-Vacher
Anti-Cancer Drugs|April 4, 2009
Hypertension and proteinuria: a class-effect of antiangiogenic therapiesVincent Launay-Vacher, Gilbert Deray
Cancer Treatment Reviews|May 25, 2011
Importance of monitoring renal function in patients with cancerMatti Aapro, Vincent Launay-Vacher
Bulletin Du Cancer|December 3, 2011
[Treatments of metastases in cancer]Joseph Gligorov, Vincent Launay-Vacher, Matti Aapro
The New England Journal of Medicine|September 9, 2005
Viral load and HIV-associated nephropathyHassane Izzedine, Marc Wirden, Vincent Launay-Vacher
Pageof 13